CN103432497B - External preparation for treating haemorrhoids - Google Patents
External preparation for treating haemorrhoids Download PDFInfo
- Publication number
- CN103432497B CN103432497B CN201310407920.0A CN201310407920A CN103432497B CN 103432497 B CN103432497 B CN 103432497B CN 201310407920 A CN201310407920 A CN 201310407920A CN 103432497 B CN103432497 B CN 103432497B
- Authority
- CN
- China
- Prior art keywords
- parts
- external preparation
- hemorrhoid
- treat
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 239000002674 ointment Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 11
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 8
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 8
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 8
- 239000003871 white petrolatum Substances 0.000 claims description 8
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 229960004063 propylene glycol Drugs 0.000 claims description 4
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 8
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 244000173853 Sanguisorba officinalis Species 0.000 abstract description 2
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241001278836 Agrimonia pilosa Species 0.000 abstract 1
- 235000000641 Agrimonia pilosa Nutrition 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 36
- 238000011282 treatment Methods 0.000 description 25
- 239000000843 powder Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 240000001624 Espostoa lanata Species 0.000 description 8
- 235000009161 Espostoa lanata Nutrition 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 208000035861 hematochezia Diseases 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000000664 rectum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010027514 Metrorrhagia Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000402754 Erythranthe moschata Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- -1 liquid paraffin Natural products 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241000517307 Pediculus humanus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 240000000774 Cunila origanoides Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- 241001299817 Dictamnus Species 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000417534 Stemona sessilifolia Species 0.000 description 1
- 241000244978 Stemonaceae Species 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external preparation for treating haemorrhoids. The external preparation comprises active ingredients and auxiliary materials acceptable in pharmaceutical science, wherein the active ingredients are prepared through water extract and alcohol precipitate by the following traditional Chinese medicinal materials in parts by weight: 8-13 parts of sanguisorba officinalis, 8-13 parts of honeysuckle, 8-13 parts of radix stemonae, 10-18 parts of ligusticum wallichii, 10-18 parts of sophora flower, 10-18 parts of agrimonia pilosa, 10-18 parts of purslane, 25-35 parts of burdock, and 25-35 parts of cortex dictamni. Through combined actions of stopping blood, improving microcirculation, diminishing inflammation and easing pain, the external preparation can treat the haemorrhoids once and for all.
Description
Technical field
The invention belongs to medical art, relate to a kind of pharmaceutical composition for the treatment of hemorrhoid, particularly relate to a kind of external preparation for the treatment of hemorrhoid.
Background technology
Hemorrhoid are a kind of common property, multiple characteristic of disease anal and intestinal disease, hemorrhoid are under rectum end mucosa and under anal canal skin, the soft vein agglomerate expanded and flexing is formed occurs venous plexus, main clinical manifestation for having blood in stool, pain, edema, falling inflation, pruritus, secretions increase and the symptom such as to deviate from, relevant research shows, the sickness rate of China's hemorrhoid is about 46%, reach 70% in some district, sickness rate that is American-European, Japan Data investigation is about 40%-60%.Having blood in stool, deviating from and the symptoms such as pain appears because of hemorrhoid in many patients, has had a strong impact on life, working and learning, so there is the exploitation of the hemorrhoid treating medicine of good result to have great importance.
The method of current treatment hemorrhoid mainly contains Drug therapy, surgical ligation and injection treatment.Anorectal educational circles of China has held the sick symposium of national hemorrhoid in April, 2000 in Chengdu, to explicitly pointing out in the new definition of hemorrhoid " objects of all treatments are not eliminate hemorrhoid bodies; but eliminate symptom; and the symptom removing hemorrhoid is more meaningful than change hemorrhoid body size, should be considered the standard of therapeutic effect ".These new treatment concept make the Therapeutic Principle of hemorrhoid clear, and the non-operative treatment importance that especially basic pharmaceutical is treated is appeared suddenly.Now mostly the suggestion of scholar be more than ninety percent hemorrhoid patients can adopt non-operative treatment, only need surgical intervention less than the hemorrhoid patients of 10%.Reason is Drug therapy energy reducing swelling and alleviating pain, relief of symptoms, turn avoid the pain of operation and the complication of injection treatment, so most people is applicable to Drug therapy.Medicine at present for hemorrhoid mainly contains antibiotics, hemorrhage and Chinese patent medicine, front two class medicines often take stopgap measures refractory this, recurrence probability is large, of long duration often can worsen.In addition, at present drug treatment takes for oral administration or topical patch to need systemic Absorption to treat relieving constipation medicine in addition clinically, this kind of drug main will rely on softening stool, the impact of stool to anus blood stasis is reduced during defecation, thus alleviate the misery of hemorrhoid patients, but the basic state of an illness that this kind of medicine does not change hemorrhoid patients does not change the cause of disease in other words conj.or perhaps, and in fact the state of an illness is under development.
Summary of the invention
In view of the deficiencies in the prior art, the object of the present invention is to provide and a kind of there is antiinflammatory, analgesia, hemostasis, improve the external used medicine of the treatment hemorrhoid of vascular permeability effect.
In order to realize object of the present invention, inventor is studied by lot of experiments, finally obtains following technical scheme:
A kind of external preparation for the treatment of hemorrhoid, comprise active component and pharmaceutically acceptable adjuvant, described active component is prepared from through water extract-alcohol precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Radix Sanguisorbae 8-13 part, Flos Lonicerae 8-13 part, Radix Stemonae 8-13 part, Rhizoma Chuanxiong 10-18 part, Flos Sophorae 10-18 part, Herba Agrimoniae 10-18 part, Herba portulacae 10-18 part, Fructus Arctii 25-35 part, Cortex Dictamni 25-35 part.
The external preparation for the treatment of hemorrhoid of the present invention, active component wherein is preferably prepared from through water extract-alcohol precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Radix Sanguisorbae 10 parts, Flos Lonicerae 10 parts, the Radix Stemonae 10 parts, Rhizoma Chuanxiong 14 parts, 14 parts, Flos Sophorae, Herba Agrimoniae 14 parts, Herba portulacae 14 parts, Fructus Arctii 30 parts, Cortex Dictamni 30 parts.
The external preparation of above-mentioned treatment hemorrhoid can be prepared into gel, ointment, suppository or ointment.
Further preferably, when the external preparation of above-mentioned treatment hemorrhoid is prepared into gel, wherein said pharmaceutically acceptable adjuvant is selected from the two or more of carbomer, propylene glycol, glycerol, triethanolamine and cellulose derivative.
Further preferably, when the external preparation of above-mentioned treatment hemorrhoid is prepared into ointment, it is two or more that wherein said pharmaceutically acceptable adjuvant is selected from glyceryl monostearate, glycerol, propylene glycol, stearic acid, white vaseline, triethanolamine, sodium lauryl sulphate and ethyl hydroxybenzoate.
Further preferably, when the external preparation of above-mentioned treatment hemorrhoid is prepared into suppository, it is two or more that wherein said pharmaceutically acceptable adjuvant is selected from semi-synthetic fatty glyceride, glycerol, gelatin and Polyethylene Glycol.
Further preferably, when the external preparation of above-mentioned treatment hemorrhoid is prepared into ointment, it is two or more that wherein said pharmaceutically acceptable adjuvant is selected from glyceryl monostearate, paraffin, white vaseline, liquid paraffin, propylene glycol, P-hydroxybenzoic acid second and sorbester p17.
It should be noted that, according to Chinese medicine Historical Data Data About, the Chinese crude drug selected by the present invention has following function and cures mainly and originate:
Radix Sanguisorbae: cooling blood for hemostasis, heat-clearing and toxic substances removing, detumescence sore.Spit blood, spitting of blood, epistaxis, hematuria, has blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, leucorrhea with red and white discharge, sore, carbuncle and painful swelling, eczema, pudendal pruritus, burn due to hot liquid or fire, snake bite and insect sting.Select the dry root of rosaceous plant Radix Sanguisorbae Sanguisorba officinalis L..
Flos Lonicerae: heat-clearing and toxic substances removing.Epidemic febrile disease is generated heat; Toxic-heat and blood stasis; Carbuncle furuncle; Sore throat and multi-infection disease.Be selected from the dry flower of caprifoliaceae plant Radix Ophiopogonis (Lonicera japonica Thunb).
The Radix Stemonae: nourishing the lung to keep the adverse QI downward cough-relieving, parasite killing.Cough for new chronic cough, pulmonary tuberculosis cough, pertussis; Outer for head louse, body louse, enterobiasis, pudendum Pruritus.Honey Radix Stemonae nourishing the lung to arrest cough.Be selected from the dried root of Stemonaceae plant Radix Stemonae Stemona sessilifolia (Miq.) Miq..
Rhizoma Chuanxiong: blood-activating and qi-promoting, wind-expelling pain-stopping.For pacifying nerve, positive wind syndrome of head headache, lump in the abdomen is suffered from abdominal pain, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia.Select the rhizome of samphire Rhizoma Chuanxiong.
Flos Sophorae: cooling blood for hemostasis; Liver heat removing and eyesight improving.Main discharging fresh blood stool; Hemorrhoid hematochezia; Dysentery; Hematuria; Stranguria with blood; Metrorrhagia; Spit blood; Epistaxis; Liver-heat is had a headache; Conjunctival congestion and swelling pain; Carbuncle skin infection.For having blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, spit blood, epistaxis, liver-heat conjunctival congestion, has a headache dizzy.
Herba Agrimoniae: astringing to arrest bleeding, dysentery relieving, parasite killing.Be widely used in various hemorrhage card, such as: haematemesis, hematuria, have blood in stool, metrorrhagia, spitting of blood, epistaxis, dysentery, impairment caused by overstrain takes off power, carbuncle, traumatic injury, the cards such as wound hemorrhage.
Herba portulacae: heat-clearing and toxic substances removing, diuretic dries, loose blood detumescence, dust-collection sterilization, anti-inflammatory analgetic, hemostasis removing heat from blood.Cure mainly dysentery, enteritis, nephritis, puerperal, metrorrhagia, had blood in stool, the diseases such as mastitis.Select the young young stem and leaf of portulacaceous plant Herba Portulacae.
Fructus Arctii: the effect with dispelling wind and heat pathogens, lung qi dispersing rash, sore-throat relieving eliminating stagnation, removing toxic substances and promoting subsidence of swelling, cure mainly cough due to pathogenic wind-heat, laryngopharynx swelling and pain, macule not thoroughly, rubella pruritus, sore swollen toxin.Be selected from the dry mature fruit of feverfew Fructus Arctii Arctium lappa L..
Cortex Dictamni: heat clearing and damp drying; Dispelling wind for relieving itching; Removing toxic substances.Cure mainly the rubella caused by wind heat noxious dampness; Eczema; Scabies; Jaundice; Damp-heat arthralgia.Select the root bark of rutaceae shaggy-fruited dittany and Dictamnus angustifolius.
By the preparation technology of above-mentioned each traditional Chinese medicinal material raw materials preparation cost invention external preparation be: take Radix Sanguisorbae 8-13 part, Flos Lonicerae 8-13 part, Radix Stemonae 8-13 part, Rhizoma Chuanxiong 10-18 part, Flos Sophorae 10-18 part, Herba Agrimoniae 10-18 part, Herba portulacae 10-18 part, Fructus Arctii 25-35 part and the mixing of Cortex Dictamni 25-35 part, add the water of 10-12 times amount, soak 12h-16h, then decoct three times, first time decocts 1.5-2h, leaches medicinal liquid stand-by, second time adds the water of 8-10 times amount, decocts 1-1.5h, leaches medicinal liquid stand-by, add the water of 6-8 times amount for the third time, decoct 0.8-1h, leach medicinal liquid stand-by, merge three decocting liquids, filter, collect filtrate, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is about 1.25 to relative density when 65 DEG C (relative water), and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder; By clear paste powder and pharmaceutically acceptable adjuvant conveniently technique be prepared into gel, ointment, suppository or ointment.
Chinese medicine for external application provided by the present invention reaches effect of radical cure hemorrhoid by the comprehensive functions such as microcirculation, antiinflammatory, analgesia of stopping blooding, improve, and is applicable to the intractable hemorrhoid for the treatment of, is especially applicable to treating hemorrhagic hemorrhoid.Found by animal experiment study, Chinese medicine for external application of the present invention can suppress the auris dextra swelling of caused by dimethylbenzene xylene inflammation mouse model, reduce the rectum vein permeability of Oleum Tiglii hemorrhoid rat model, analgesic effect is also comparatively remarkable, and the first-line drug that can be used as hemorrhoid treating is developed simultaneously.In addition, formula of the present invention not only can play respective effect of component, can embody again the cooperative effect of said components, mutual penetration enhancement, enhance the therapeutic effect of hemorrhoid.
Specific embodiment
We find in screening experiment, and in pharmaceutical composition of the present invention, the consumption of often kind of traditional Chinese medicinal material raw materials slightly changes among a small circle, and it all has the biological activity for the treatment of hemorrhoid.Now further illustrate pharmaceutical composition of the present invention and preparation method thereof and therapeutic effect by following embodiment, but protection scope of the present invention is not limited to embodiment.
The preparation of embodiment 1 Chinese medicine clear paste powder
Take Radix Sanguisorbae 10 parts, Flos Lonicerae 10 parts, the Radix Stemonae 10 parts, Rhizoma Chuanxiong 14 parts, 14 parts, Flos Sophorae, Herba Agrimoniae 14 parts, Herba portulacae 14 parts, Fructus Arctii 30 parts and Cortex Dictamni 30 parts mixing, add the water of 12 times amount, soak 12h-16h, then decoct three times, first time decocts 1.5-2h, leaches medicinal liquid stand-by, second time adds the water of 10 times amount, decocts 1-1.5h, leaches medicinal liquid stand-by, add the water of 8 times amount for the third time, decoct 0.8-1h, leach medicinal liquid stand-by, merge three decocting liquids, filter, collect filtrate, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is about 1.25 to relative density when 65 DEG C (relative water), and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder.
The preparation of embodiment 2 Chinese medicine gel
Chinese medicine clear paste powder 20g
Carbomer 15g
Propylene glycol 75ml
Glycerol 75ml
Triethanolamine is appropriate
Purified water adds to 1000ml
Preparation technology: carbomer is slowly joined in the water of recipe quantity about 50%, limit edged stirs until form transparent gel-type vehicle, Chinese medicine clear paste powder embodiment 1 prepared is dissolved in suitable quantity of water, add again in substrate, stir, add propylene glycol, glycerol, purified water to full dose, triethanolamine adjust ph, to neutral, to obtain final product.
The preparation of embodiment 3 Chinese medicine ointment
Chinese medicine clear paste powder 20g
Glyceryl monostearate 100g
Paraffin 100g
White vaseline 50g
Liquid paraffin 55g
Propylene glycol 50g
Sorbester p17 6g
Ethylparaben 1.2g
Purified water adds to 1000ml
Preparation technology: get paraffin, glyceryl monostearate, white vaseline, liquid paraffin, propylene glycol, sorbester p17 and ethylparaben heat fused keep 80 DEG C in water-bath, the water of 80 DEG C is slowly added under stirring, limit edged is stirred to condensation, i.e. ointment base.Get Chinese medicine clear paste powder to be dissolved in appropriate purified water, join in substrate, finally add water to full dose, to obtain final product.
The preparation of embodiment 4 Chinese medicine suppository
Chinese medicine clear paste powder 20g
Semi-synthetic fatty glyceride 350g
Tween 80 1.5g
Preparation technology: get semi-synthetic fatty glyceride and put in vessel, heating in water bath melts, and treats that temperature is down to about 50 DEG C, add Tween 80, stir, add Chinese medicine clear paste powder, stir, rear injection scribbles the bolt mould of lubricant to slightly overflowing die orifice for degree, cooling, spilling of pruning after solidifying part, the demoulding, quality inspection, packaging, to obtain final product.
The preparation of the blank ointment of comparative example
Glyceryl monostearate 100g
Paraffin 100g
White vaseline 50g
Liquid paraffin 55g
Propylene glycol 50g
Sorbester p17 6g
Ethylparaben 1.2g
Purified water adds to 1000ml
Preparation technology: get paraffin, glyceryl monostearate, white vaseline, liquid paraffin, propylene glycol, sorbester p17 and ethylparaben heat fused keep 80 DEG C in water-bath, the purified water of 80 DEG C is slowly added under stirring, limit edged is stirred to condensation, i.e. blank ointment.
Embodiment 5 Chinese medicine ointment is on the impact of rat Oleum Tiglii hemorrhoid model
Modeling method: Oleum Tiglii is a kind of conventional proinflammatory agent, conventional Oleum Tiglii mixed liquor 1 part of distilled water, 4 parts of pyridines, 5 parts of ether and 10 part of 15% Oleum Tiglii diethyl ether solution preparation.Be stained with Oleum Tiglii with 10mg cotton balls, the cotton balls after soaking put into rat anal, stops and take out after 15 seconds.
36 SD rats (about 200 grams) are divided into three groups at random by body weight: model control group (the blank ointment of administration), Ma Yinglong group (administration MAYINGLONG MUSK HEMORRHOID UNGUENTUM), test group (Chinese medicine ointment prepared by administration embodiment 3), often organize 12.Rat carries a few days ago drop rectum with drug, and every day sooner or later respectively once, is stained with medicine with 10mg cotton balls, cotton balls is filled in internal rectum, during next administration, first should check whether internal rectum has cotton balls (should take out if any cotton balls).Last administration should after modeling 2 hours.Last administration is after 5 hours, every blue normal saline solution (2ml/kg) of she Wen of rat intravenous injection 1%, sacrificed by exsanguination animal after 40 minutes, cut-off intestinal and perianal tissue, use acetone normal saline 7:3 solution soaking 48 hours after weighing, centrifugal 10 minutes of 3000rpm, gets supernatant and surveys absorbance in 590nm, as evaluation vascular permeability index, the results are shown in Table 1.
Can be found out by the result of the test of table 1, Chinese medicine ointment of the present invention well can reduce the rectum vein permeability of Oleum Tiglii hemorrhoid model mice, with Ma Yinglong group there was no significant difference.
The comparison of each treatment group of table 1 and model control group absorbance
| Group | Rat number of elements | Absorbance |
| Model control group | 12 | 0.150±0.041 |
| Ma Yinglong group | 12 | 0.107±0.046 ★ |
| Test group | 12 | 0.113±0.030 ★ |
★compare with matched group, P < 0.05;
★ ★compare with matched group, P < 0.01.
Embodiment 6 Chinese medicine ointment is on the impact of mice dimethylbenzene inflammatory model
36 KM mices, male and female half and half, body weight 25-30 gram, is divided into three groups at random by body weight: model control group (the blank ointment of administration), Ma Yinglong group (administration MAYINGLONG MUSK HEMORRHOID UNGUENTUM), test group (Chinese medicine ointment prepared by administration embodiment 3), often organizes 12.Get dimethylbenzene 20 μ l, be applied to mouse right ear.Get after 30min and be respectively evenly applied to mouse right ear respectively by reagent, put to death after administration 3h.Along auricle baseline, place cuts two ears, lays auricle, weigh with 8mm card punch at the same position of left and right ear, and the ear method of double differences=auris dextra sheet weight-left auricle weight, the results are shown in Table 2.
Can be found out by the result of the test of table 2, Chinese medicine ointment of the present invention has obvious antiinflammatory action, and antiinflammatory curative effect is better than Ma Yinglong treatment group.
The each treatment group of table 2 and the model control group ear method of double differences compare
| Group | Rat number of elements | The ear method of double differences (mg) |
| Model control group | 12 | 7.17±2.47 |
| Ma Yinglong group | 12 | 4.97±2.61 ★ |
| Test group | 12 | 3.08±1.83 ★★● |
★compare with matched group, P < 0.05;
★ ★compare with matched group, P < 0.01;
●with Ma Yinglong group comparatively, P < 0.05;
● ●compare with Ma Yinglong group, P < 0.01.
Embodiment 7 Chinese medicine ointment is on the impact of pain model in mice
KM mice 36, male and female half and half, body weight 25-30 gram, is divided into three groups at random by body weight: model control group (the blank ointment of administration), Ma Yinglong group (administration MAYINGLONG MUSK HEMORRHOID UNGUENTUM), test group (Chinese medicine ointment prepared by administration embodiment 3), often organizes 12.Mice anum administration, is stained with medicine with 10mg cotton balls, cotton balls is filled in internal rectum, once a day, continuous three days, after last administration 30 minutes, injects 5% formalin 0.2ml apart from anus 3.5cm place rectal wall.Writhing number of times in record mice 20 minutes.Concrete outcome is in table 3.
Can be found out by the result of the test of table 2, Chinese medicine ointment of the present invention has fairly obvious analgesic effect, with Ma Yinglong group there was no significant difference.
The each treatment group of table 3 and model control group writhing number of times compare
| Group | Rat number of elements | Writhing number of times |
| Model control group | 12 | 48.3±11.7 |
| Ma Yinglong group | 12 | 36.7±12.6 ★ |
| Test group | 12 | 33.0±15.1 ★ |
★compare with matched group, P < 0.05;
★ ★compare with matched group, P < 0.01.
Claims (7)
1. treat the external preparation of hemorrhoid for one kind, comprise active component and pharmaceutically acceptable adjuvant, it is characterized in that described active component is prepared from through water extract-alcohol precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Radix Sanguisorbae 8-13 part, Flos Lonicerae 8-13 part, Radix Stemonae 8-13 part, Rhizoma Chuanxiong 10-18 part, Flos Sophorae 10-18 part, Herba Agrimoniae 10-18 part, Herba portulacae 10-18 part, Fructus Arctii 25-35 part, Cortex Dictamni 25-35 part.
2. treat the external preparation of hemorrhoid according to claim 1, it is characterized in that described active component is prepared from through water extract-alcohol precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Radix Sanguisorbae 10 parts, Flos Lonicerae 10 parts, the Radix Stemonae 10 parts, Rhizoma Chuanxiong 14 parts, 14 parts, Flos Sophorae, Herba Agrimoniae 14 parts, Herba portulacae 14 parts, Fructus Arctii 30 parts, Cortex Dictamni 30 parts.
3. according to claim 1 or 2, treat the external preparation of hemorrhoid, it is characterized in that: described external preparation is gel, ointment, suppository or ointment.
4. treat the external preparation of hemorrhoid according to claim 3, it is characterized in that: when described external preparation is gel, described pharmaceutically acceptable adjuvant is selected from the two or more of carbomer, propylene glycol, glycerol, triethanolamine and cellulose derivative.
5. treat the external preparation of hemorrhoid according to claim 3, it is characterized in that: when described external preparation is ointment, it is two or more that described pharmaceutically acceptable adjuvant is selected from glyceryl monostearate, glycerol, propylene glycol, stearic acid, white vaseline, triethanolamine, sodium lauryl sulphate and ethyl hydroxybenzoate.
6. treat the external preparation of hemorrhoid according to claim 3, it is characterized in that: when described external preparation is suppository, it is two or more that described pharmaceutically acceptable adjuvant is selected from semi-synthetic fatty acid glyceride, glycerol, gelatin and Polyethylene Glycol.
7. treat the external preparation of hemorrhoid according to claim 3, it is characterized in that: when described external preparation is ointment, it is two or more that described pharmaceutically acceptable adjuvant is selected from glyceryl monostearate, paraffin, white vaseline, propylene glycol, P-hydroxybenzoic acid second and sorbester p17.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310407920.0A CN103432497B (en) | 2013-09-10 | 2013-09-10 | External preparation for treating haemorrhoids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310407920.0A CN103432497B (en) | 2013-09-10 | 2013-09-10 | External preparation for treating haemorrhoids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103432497A CN103432497A (en) | 2013-12-11 |
| CN103432497B true CN103432497B (en) | 2015-05-20 |
Family
ID=49686281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310407920.0A Active CN103432497B (en) | 2013-09-10 | 2013-09-10 | External preparation for treating haemorrhoids |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103432497B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266301A (en) * | 2015-06-04 | 2017-01-04 | 刘飞德 | A kind of Chinese medicine composition treating inflammatory external hemorrhoid and preparation method thereof |
| CN105169456B (en) * | 2015-08-25 | 2018-06-01 | 东莞市达庆医疗器械有限公司 | A kind of medical bio hemorrhoid hydrogel functional dressing and preparation method thereof |
| CN105943655A (en) * | 2016-05-04 | 2016-09-21 | 昆明理工大学 | Compound ointment for treating hemorrhoids and preparation method of compound ointment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000175A (en) * | 2010-11-17 | 2011-04-06 | 黄文珍 | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof |
| CN102772598A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating bacillary dysentery |
-
2013
- 2013-09-10 CN CN201310407920.0A patent/CN103432497B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000175A (en) * | 2010-11-17 | 2011-04-06 | 黄文珍 | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof |
| CN102772598A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating bacillary dysentery |
Non-Patent Citations (1)
| Title |
|---|
| 肛肠安胶囊治疗痔疮188例疗效观察;赵国鸣等;《云南中医中药杂志》;20091231;第30卷(第10期);37-38 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103432497A (en) | 2013-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205026B (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN102698022B (en) | Externally-used pharmaceutical formulation for nursing or treating haemorrhoids | |
| CN105998334A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating haemorrhoids | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN102920955A (en) | External traditional Chinese medicine composition for treating dermatophytosis, preparation method and application | |
| CN104740458A (en) | Pruritus treating traditional Chinese medicine composition | |
| CN103432497B (en) | External preparation for treating haemorrhoids | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN104491156B (en) | A kind ofly treat Chinese medicine composition of hemorrhagic hemorrhoid and preparation method thereof | |
| CN103977362A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and early-stage breast cancer | |
| CN103908600B (en) | The external used medicine for the treatment of rheumatoid arthritis damp-heat arthralgia resistance card and preparation method | |
| CN102028911A (en) | External medicament for treating tinea pedis | |
| CN104524477A (en) | Traditional Chinese medicine composition for treating nodular goiter | |
| CN106668782A (en) | External traditional Chinese medicine preparation for treating knee osteoarthritis and preparation method thereof | |
| CN103432501A (en) | Traditional Chinese medicine composition for treating chronic colitis and preparation method of preparation thereof | |
| CN105616536A (en) | Traditional Chinese medicine liniment for treating leukoderma | |
| CN105213726A (en) | A kind of Chinese medicine composition for the treatment of hemorrhoid | |
| CN104644860A (en) | Medicine composition for treating inflammatory external hemorrhoids of pregnant and lying-in women and application thereof | |
| CN111743982A (en) | Vulva lotion and preparation method thereof | |
| CN104189489A (en) | Medicament with effect of treating chronic eczema and preparation method thereof | |
| CN106310049A (en) | Traditional Chinese medicine granule for treating anorectal diseases and preparation method thereof | |
| CN105396007A (en) | Gynecological topical lotion for preventing and treating colpitis mycotica | |
| CN105535225A (en) | Medicinal composition for treating colitis and application of medicinal composition | |
| CN104491747A (en) | Traditional Chinese medicine tablets for treating pelvic inflammatory disease and preparation method thereof | |
| CN104027781A (en) | Traditional Chinese medicine composition for treating chilblain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI JIAN Free format text: FORMER OWNER: YU HAO Effective date: 20150331 |
|
| CB03 | Change of inventor or designer information |
Inventor after: Li Jian Inventor before: Yu Hao |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 235000 HUAIBEI, ANHUI PROVINCE TO: 241000 WUHU, ANHUI PROVINCE Free format text: CORRECT: INVENTOR; FROM: YU HAO TO: LI JIAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150331 Address after: Jinghu District of Anhui city of Wuhu province Jiuhua Road 241000 No. 263 Wuhu Second People's Hospital Applicant after: Li Jian Address before: Dongshan Road Xiangshan District 235000 Anhui city of Huaibei province Anhui BBCA Biochemical Limited by Share Ltd Applicant before: Yu Hao |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160620 Address after: Jinghu District of Anhui city of Wuhu province Jiuhua Road 241000 No. 263 Wuhu Second People's Hospital Patentee after: Wuhu No.2 Peoples Hospital Address before: Jinghu District of Anhui city of Wuhu province Jiuhua Road 241000 No. 263 Wuhu Second People's Hospital Patentee before: Li Jian |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200921 Address after: 1809, unit 1, nut apartment, 225 Huaqing West Road, Xincheng District, Xi'an City, Shaanxi Province Patentee after: Xi'an Rongke Network Technology Co., Ltd Address before: Jinghu District of Anhui city of Wuhu province Jiuhua Road 241000 No. 263 Wuhu Second People's Hospital Patentee before: WUHU NO.2 PEOPLE'S Hospital |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220413 Address after: 715400 Building 8, Wujing Road North, management committee of Xincheng economic and Technological Development Zone, Hancheng City, Weinan City, Shaanxi Province Patentee after: Shaanxi enbekang Biotechnology Co.,Ltd. Address before: 710065 1809, unit 1, nut apartment, 225 Huaqing West Road, Xincheng District, Xi'an City, Shaanxi Province Patentee before: Xi'an Rongke Network Technology Co.,Ltd. |